stoxline Quote Chart Rank Option Currency Glossary
BioNTech SE (BNTX)
98.75  5.52 (5.92%)    05-30 16:00
Open: 94
High: 103.4
Volume: 2,728,225
Pre. Close: 93.23
Low: 92.39
Market Cap: 23,475(M)
Technical analysis
2024-05-30 4:40:13 PM
Short term     
Mid term     
Targets 6-month :  120.77 1-year :  141.06
Resists First :  103.4 Second :  120.77
Pivot price 94.22
Supports First :  92.72 Second :  86.12
MAs MA(5) :  96.4 MA(20) :  93.63
MA(100) :  93.16 MA(250) :  101.02
MACD MACD :  1.7 Signal :  1.3
%K %D K(14,3) :  43.1 D(3) :  46.2
RSI RSI(14): 60.1
52-week High :  125.83 Low :  85.21
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ BNTX ] has closed below upper band by 15.4%. Bollinger Bands are 46.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 103.64 - 104.33 104.33 - 104.95
Low: 90.83 - 91.64 91.64 - 92.36
Close: 97.45 - 98.78 98.78 - 99.98
Company Description

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Headline News

Thu, 30 May 2024
BioNTech SE (NASDAQ:BNTX) Shares Sold by Artisan Partners Limited Partnership - MarketBeat

Thu, 30 May 2024
BioNTech and CEPI Boost Africa's Vaccine Production - - TipRanks

Wed, 29 May 2024
BioNTech SE ADR falls Wednesday, underperforms market - MarketWatch

Wed, 29 May 2024
BioNTech SE ADR falls Wednesday, underperforms market - MarketWatch

Tue, 28 May 2024
BioNTech SE Sponsored ADR (BNTX) Gains As Market Dips: What You Should Know - Yahoo New Zealand News

Tue, 28 May 2024
BioNTech SE ADR falls Tuesday, underperforms market - MarketWatch

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 241 (M)
Shares Float 89 (M)
Held by Insiders 62.8 (%)
Held by Institutions 18.2 (%)
Shares Short 3,160 (K)
Shares Short P.Month 3,080 (K)
Stock Financials
EPS 4.11
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 85.16
Profit Margin 24.3 %
Operating Margin 40 %
Return on Assets (ttm) 2.6 %
Return on Equity (ttm) 4.6 %
Qtrly Rev. Growth -65.5 %
Gross Profit (p.s.) 0
Sales Per Share 15.85
EBITDA (p.s.) 4.6
Qtrly Earnings Growth -79.5 %
Operating Cash Flow 5,370 (M)
Levered Free Cash Flow 4,140 (M)
Stock Valuations
PE Ratio 24.02
PEG Ratio 1.1
Price to Book value 1.15
Price to Sales 6.22
Price to Cash Flow 4.43
Stock Dividends
Dividend 2.1
Forward Dividend 0
Dividend Yield 2.1%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android